{
  "doc_id": "dlgcg_hepatocellulart-carcinom_v.3.0_admgodk_181224",
  "created_date": "2024",
  "country": "DK",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "sline sline •me me DLGCG",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "CLINICAL GUIDELINES • CANCER",
      "text": "liver liver cancer",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Version 3.0",
      "text": "2024 2024 (DLGCG) 2024 2024 [of of Cancer]",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "AUDIT",
      "text": "Scheduled: April 30, 2026",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "INDECTION",
      "text": "njeaf njeaf inje",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "New Recommendation 13",
      "text": "transplant transplant (B) Recommendation 15 (formerly 14) changed changed from: (el el SIRT) to (el el SBRT)",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "New Recommendation 25",
      "text": "Radioembolism (radiotherapy radiotherapy (SIRT)) transplantation transplantation (C).",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "amended amended from:",
      "text": "you you see?That'and and that's how I'be be doing?It's why I'but but I'it. it.I'now. now.We'TACE TACE can'or or isn'use use (A) below below (A] line line (A). 1. Recommendations (Quick guide) ...... Monitoring........................................................................................................",
      "start_page": 2,
      "end_page": 4
    },
    {
      "heading": "Monitoring",
      "text": "study study (A)",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Diagnostics",
      "text": "monitoring monitoring (C) modality modality (MR/CT/ expert expert centers) algorithm algorithm above) (B) Hsp. Hsp.",
      "start_page": 5,
      "end_page": 6
    },
    {
      "heading": "or or multifocal",
      "text": "function function (B) 10.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Liver transplantation",
      "text": "met met (B) 13.",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "Ablation",
      "text": "treatment treatment (tumours tumours < 3 cm) (A) 20.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "Radiation treatment",
      "text": "radiotherapy radiotherapy (SBRT) resection resection (C) 25. 25.",
      "start_page": 7,
      "end_page": 8
    },
    {
      "heading": "Non-curative treatment",
      "text": "patients patients (score score ≤ downstaging downstaging (A)",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "indicated indicated (A)",
      "text": "therapy therapy (C)",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "Systemic treatment",
      "text": "or or TACE/disease disease (A) line line (A), 31. ~and and •function function (C)",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "and and adolescents",
      "text": "of of Children'or or Child'Hospital. Hospital.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "2. Introduction",
      "text": "carcinoma carcinoma (HCC) men men > 60 years (1.2). in in 70-80% cirrhosis cirrhosis (about 65%) overuse overuse (2). Hep Hep B+ function function (as as hepatolog), HPB surgeons/ patients. patients.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Monitoring",
      "text": "study study (A)",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "months months (C)",
      "text": "following following groups: Chronic hepatitis B: patients patients & Products Products (3).",
      "start_page": 10,
      "end_page": 11
    },
    {
      "heading": "Screening method",
      "text": "Alphafetoprotein Alphafetoprotein (AFP) of of 78-90% and with 93% specificity (5-12).",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Screening interval",
      "text": "interval. interval.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Diagnostics",
      "text": "monitoring monitoring (C) modality modality (MR/CT/ expert expert centers) algorithm algorithm above) (B) Hsp. Hsp.",
      "start_page": 11,
      "end_page": 12
    },
    {
      "heading": "cirrhosis cirrhosis (C)",
      "text": "out out (washout) phase phase and/phase phase (13-17). sequences sequences (see Figure 1). tendon tendon (interstitial) noduli noduli < lesions lesions > liver liver (MDCT = multidetected CT scanning). with with venostic",
      "start_page": 12,
      "end_page": 13
    },
    {
      "heading": "the the HCC",
      "text": "routine routine PET/about about 50-65% 68Ga-PSMA, 68Ga-PSMA, 11C/18F 18F -both both intra- with with 18F",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Diagnosis - Pathology",
      "text": "embedded. embedded.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Macroscopy",
      "text": "as as follows: guideline guideline (31), invasion invasion (MVI), are are taken: cut cut (E), liver liver (A-D), tissue tissue (F-G) and and > area. area.",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "Microscopy",
      "text": "guidelines guidelines (31-34): type type (ad-modum ad-modum Steiner) including including satelliteosis* changes changes * parenchym parenchym (35) marker marker (36). studies. studies.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Early HCC",
      "text": "noduli noduli (Nodulus Nodulus (LGDN) nodulus, nodulus, HGDN) difficult. difficult.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "HCC HCC (37.38).",
      "text": "Barcelona Barcelona clinic'lesions lesions (37, 38, 40). lesions lesions (24, 40). is is unknown; these these HCC- HCC HCC (44) 3 3 markers: synthetase synthetase (diffus positivity), al. al.(45) in in 100% nodul nodul (LGDN), 73% nodule nodule (HGDN) and 3% no no LGDN/agents. agents.",
      "start_page": 15,
      "end_page": 16
    },
    {
      "heading": "TNM classification",
      "text": "year. year.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "T-primary tumour:",
      "text": "tumor tumor > is is > a a > T4 T4 Tumor(s) organs organs (including diaphragma) visceral visceral peritoneum",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "N • Regional lymph nodes:",
      "text": "hepatic hepatic (hepatic hepatic communis), periportals (long v. portae), nodule nodule metastasis(r)",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "M• Remote metastases:",
      "text": "Remote Remote metastasis",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Alpha Fetoprotein",
      "text": "origin origin (tumors tumors (47)), common common (48). hepatitis hepatitis (49, 50) metastases metastases (51, 52). to to 40% HCC HCC (53). radiological radiological and/HPC. HPC.",
      "start_page": 17,
      "end_page": 18
    },
    {
      "heading": "or or multifocal",
      "text": "following following algorithm: Clinical Guideline (HCC), function function (B) indicated indicated (B). treatment treatment (C) Stadding Stadding (staging) be be used(7, 54-60).",
      "start_page": 18,
      "end_page": 19
    },
    {
      "heading": "Reference (12)",
      "text": "Treatment Treatment options:",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "• Liver section",
      "text": "• Transplantation • Ablation • SBRT • SIRT • Protons (protocoled)",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "HCC. HCC. Tumor",
      "text": "resection resection (52.59). ence ence (MDT) diameter diameter ≥ HCC HCC ≥ survival survival (60). after after resection; (61). survival survival (62.63). RFA RFA (64). ablation ablation and/chemoembolism chemoembolism (TACE) survival survival (70).",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Liver transplantation",
      "text": "met met (B) 13.",
      "start_page": 20,
      "end_page": 21
    },
    {
      "heading": "indicated indicated (C)",
      "text": "hepatocellular hepatocellular carcinoma: report report (71). references references (72, 73). approximately approximately 70%. certain certain biomarkers; prognosis prognosis (74). below. below.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Milan criteria",
      "text": "number. number.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "AFP-based Crititeries",
      "text": "Shanghai Shanghai (75). The The 5-donors donors (76). criteria criteria (tumor size ≤ number number ≤ AFP AFP ≤ 500 ng/ml) 7. 7.3% period period (77).",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "0 0 algorithm",
      "text": "stated. stated.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Ablation",
      "text": "treatment treatment (tumours tumours < 3 cm) (A) possible possible (C) cm cm (A), indicated indicated (C).",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "percutaneous percutaneous (closed), laporotomy laporotomy (open).",
      "text": "resection. resection. Indications:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "HCC. HCC.",
      "text": "be be ≤ tumours tumours (78).",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "size size of",
      "text": "HCC HCC < time. time.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Survival",
      "text": "about about 95%, 60% and 25-30% year year (87.9%), 3 years (60.ù 87%) years years (42.74%) (80).",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Combination therapy",
      "text": "therapy therapy (81).",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "others. others.",
      "text": "treatment. treatment.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Radiation treatment",
      "text": "resection resection (C) treated. treated.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Radiotherapy for HCC",
      "text": "radiotherapy radiotherapy (SBRT), volume volume (83). score score >therapy therapy (84.85). of of 67-79% 1 year.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "after SBRT (86). Survival is 6-8-93% and 42-59% of of that",
      "text": "SIRT (Selective Internal Radio-Terapi) radiotherapy radiotherapy (SIRT), range range (max. max. 11mm) placebo. placebo.",
      "start_page": 24,
      "end_page": 25
    },
    {
      "heading": "Non-curative treatment",
      "text": "patients patients (score score ≤ downstaging downstaging (A)",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "indicated indicated (A)",
      "text": "therapy therapy (C) performance performance (91.92) chemoembolism chemoembolism (TACE), __MIDTERM2___ __MIDTERM2___ (93-95).",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "chemoembolism. chemoembolism.",
      "text": "for for this: At At DEB-TACE(Drug-Eluting Beads) and and DEB‐Pugh Pugh < DEB DEB -than than 50% of patients (96). between between 20-60% years years (97).",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Systemic treatment",
      "text": "or or TACE/disease disease (A) line line (A). function function (C) evidence evidence review",
      "start_page": 26,
      "end_page": 27
    },
    {
      "heading": "First line treatment",
      "text": "line line (66 66 (95% 85, 85, p<line line (Hr0.66 (95% 0,52-0.85), p<mth_MEDTERM16__ mth_MEDTERM16__ 30% vs 11% p<0.001CR 8% vs < 1%).",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "2nd line treatment:",
      "text": "III III study; published published (94). function function (Child Pugh A) __MEDTERM0_ __MEDTERM0_ ≥ for for ≥ randomised randomised 2:gain gain (50, 50,79) III_REW2. III_REW2.",
      "start_page": 27,
      "end_page": 28
    },
    {
      "heading": "later later lines",
      "text": "approximately approximately 20% survival survival (12 months OS_54% inhibitor inhibitor (040 040 (95) 240 240 (106). study study (Keynote-240), 78 78 (96.02% 0. 0.93; P=0.0035). __MIDTERM10__ __MIDTERM10__ (0. 0.86; 95.67% 1. 1.03; non- 1. 1.08). Council Council (108). mentioned. mentioned.",
      "start_page": 28,
      "end_page": 29
    },
    {
      "heading": "and and adolescents",
      "text": "or or Children'to to \"Pak\" to to \"in in Children\" by by Children\" G ospitalets",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "4. References",
      "text": "cancer cancer [Available from: primaer-lever cancer/statistik-lærkraeft/. Hepatol. Hepatol. 2020;73(5):carcinoma carcinoma [Avacocellular from: disease disease (NAFLD): treatment treatment [Awailablefrom: Jama. Jama. 1975;233(1):38-41.",
      "start_page": 30,
      "end_page": 37
    },
    {
      "heading": "Scientific evidence:",
      "text": "reputable reputable authorities",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "Strength of recommendations:",
      "text": "A - recommendation recommendation (la, lb) B - C C - basis basis (IV) Professional Professional approval: Administrative Administrative approval: n n (lIA, IIb, III) l. l. • Onushavn • interest interest • Rigshot Rigshot • interests interests • Universitet Universitet • Univers Univers over-recruitment-to-firms/economic economic support-or-ha • Universitetshop Universitetshop • opinion opinion • Universitetshospita Universitetshospita • K K • Universitetshost Universitetshost • conflict conflict • Austria Austria • Denmark Denmark • Historium • Nevervaft • Hovn • Parliament Parliament • Lords Lords • of of Commons/Life • Denmark Denmark • Aar Aar • Rad Rad • Rigshospitalet Rigshospitalet • interest interest • Univ Univ • interests interests • Universite Universite over-relation-to-firms there-greater-lovehold • Rifstår Rifstår • parliament parliament • Neverskehres • Medicines Medicines Agency's working relationship: companies/lists-over-associated-to-firms/apotetics, doctors,-updating updating DLGCG^'staff staff association-careers-and-toothlaeger njerne.",
      "start_page": 37,
      "end_page": 41
    },
    {
      "heading": "6. Monitoring",
      "text": "database. database.",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "7. Annex",
      "text": "Annex 1 (CT-protocol) slice slice scanner",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "Contrast",
      "text": "300 300 - 400 mg I/water water 1⁄2 - contrast. contrast.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "4 4 • 5 ml/be be 25-30",
      "text": "optimal optimal tumor/trigger trigger (contrast contrast administration) covered. covered.",
      "start_page": 42,
      "end_page": 43
    },
    {
      "heading": "Scan technology",
      "text": "that that you'Here Here you'Now Now you'it. it.That's where you'it. it.It'but but it'your your tumor: 1. Coronal HASTE/T2 T2 (greed/solid recovery/drive), phase phase (180 sec) phase phase (60 sec) values values (and and 800) ADC-map. ADC-map.",
      "start_page": 43,
      "end_page": 44
    },
    {
      "heading": "clinical clinical guideline",
      "text": "Groups Groups (DMCG.dk) Programme Programme (RKP). found found at:Health Health Authority'packages packages • content content • disease disease area: Service Service (Kreftplan IV) and RKPP.",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading <changed changed from:>",
      "text": "OTHERS OTHERS _WORT_REVIEW_PREW",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heading heading <changed changed from:> (column 5)",
      "text": "recommended. recommended... transplant transplant (B) Recommendation 15 (formerly 14) changed changed from: (or or SIRT) to (or or SBRT) Embolism Embolism (radiotherapy radiotherapy (SIRT)) transplantation transplantation (C). amended amended from: function. function.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heading heading <changed changed from:> (from previous page)",
      "text": "reference reference section: \"Row 1: or or TACE/disease disease (A) line line (A), 31. ~function function (C) Radioembolism Radioembolism (Selective internal radiotherapy) (SIRT) transplantation transplantation (C).",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <changed changed from:> (column column 6)",
      "text": "on on \"Row 1' and \"ROW 1', following following paragraphs:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <TNM8:>",
      "text": "Row 1: TNM8: Row 2:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "heading heading <later later lines>",
      "text": "Row 1: Row Row 2: groups groups (tremelimumab tremelimumab (300 mg) plus __MIDTERM1__ (Row Row 3: durvalumab alone [4 4 weeks] Stride), alone alone (week week ), 3. __medterm4_row 4: (twice twice daily) plus plus •MEDTERM1- Row Row 5: only. only.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "heading heading <Strike of recommendations:> (from previous page)",
      "text": "Row 1: The DLGCG^ guidelines. guidelines.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "heading heading <Strike of recommendations:> (column column 1)",
      "text": "Row 1: https://gemedidstyrelsen.dk/en/approvement/sun Row 2: enterprises/lister-over-associated-to-enterprises/apoterkere,-læger,-sick•",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "heading heading <Strike of recommendations:> (column column 1)",
      "text": "Row 1: The DLGCG^ Row Row 2: frequently. frequently.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "heading heading <Strike of recommendations:> (column column 2)",
      "text": "Row 1: Mental Affiliates- Row 2: Careers-and-Toothleagers",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "heading heading < 4 4 • 5 ml/be be 25-30>",
      "text": "Row 1: Type • 300 300 - 400 mg I/ml. Row 2: Quantity • Row Row 3: agent agent • Water 1⁄2 - Row Row 4: Salt water • Row Row 5: Phases",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "heading heading <Scan technique>",
      "text": "Row 1: (Equilibrium) •tumor. tumor.",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "heading heading <Scan technique>",
      "text": "Row 1: Detector configuration•Row Row 2: Kv·120 Row 3: Efficient mAs *250-300 Row 4: Pictures• mm mm cut",
      "start_page": 43,
      "end_page": 43
    }
  ]
}